Found 49 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a Phase 2 multicenter, open-label study evaluating rucaparib as treatment for solid tumors associated with a deleterious mutation in Homologous Recombination Repair (HRR) genes. All patients will be required to have received prior treatment with at least 1 line of life-extending therapy (if available) or have a tumor …
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as …
ASTX295 is a synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2; human homolog also known as HDM2). Study ASTX295-01 is a study with ASTX295 in subjects who are refractory or have relapsed after treatment with standard of care therapies, or for whom standard life-prolonging …
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
The purpose of this study is to continue to collect long term information on the safety of pembrolizumab or pembrolizumab-based combinations that you received or are receiving as part of the protocol you are currently enrolled in, to see how well the drug/s work and how your body reacts to …
The primary purpose of this study is to assess the safety and tolerability of an Investigational drug in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination …
study of surufatinib in combination with tislelizumab will evaluate the safety, and tolerability in patients with advanced solid tumors.
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with advanced (metastatic and/or unresectable) solid tumors.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas.
